Phase III trials completed; primary endpoints met 7/08; positive Phase II/III data reported 7/09; recommended for approval in EU 11/09 and approved in EU 2/10
Brand Elonva Generic corifollitropin alfa (SCH 900962)
Company name Merck, Schering-Plough Product type Speciality
Therapeutic category Endocrine and Diabetes Key uses Ovarian stimulation
Other Uses N/A Drug Class sustained follicle stimulant
Dosage From SC Expected Approval 2012+
FDA Filing N/A Last Update date March 30,2010
Link to pipeline report
Link to news article
Link to clinicaltrials.gov